论文部分内容阅读
利用试管双倍稀释法及纸片法测定ｌｅｖｏｆｌｏｘａｃｉｎ（ＬＶＬＸ）体外抗菌活性，并与其它１０种药物比较。结果表明ＬＶＬＸ对革兰氏阴性菌具有良好抗菌作用，尤以对痢疾杆菌、伤寒杆菌、变形杆菌、肺炎杆菌、产气杆菌、大肠杆菌作用更为突出，ＭＩＣ５０≤０．０３～０．２８μｇ／ｍｌ，ＭＩＣ９０≤０．０３～１２８μｇ／ｍｌ，抑菌率６０％～１００％；其活性为氧氟沙星的１～４倍，比诺氟沙星、头孢呋辛强，与环丙沙星、庆大霉素及头孢噻肟相当。ＬＶＬＸ抗葡萄球菌活性为所测喹诺酮中最强，与头孢唑林相当，对肺炎球菌、溶血性及草绿色链球菌作用与头孢菌素相当。ＬＶＬＸ有较强抗铜绿假单胞菌活性，ＭＩＣ５０与ＭＩＣ９０分别为０．５与６４μｇ／ｍｌ，与阿米卡星及头孢哌酮相当。ＬＶＬＸ为一广谱高效抗菌药物。
In vitro antibacterial activity of levofloxacin (LVLX) was determined by in vitro double-dilution and disk-blotting and compared with 10 other drugs. The results showed that LVLX has good antibacterial activity against Gram-negative bacteria, especially against Shigella, Salmonella typhi, Proteus, Klebsiella pneumoniae, Aerobacter aerogenes and Escherichia coli, MIC50≤0.03 ~ 0.28μg / ml, MIC90≤0.03 ~ 128μg / ml, antibacterial rate of 60% ~ 100%; the activity ofloxacin 1 ~ 4 times, than norfloxacin, cefuroxime strong, and ciprofloxacin , Gentamicin and cefotaxime quite. The anti-Staphylococcus aureus activity of LVLX was strongest in the quinolones tested, comparable to that of cefazolin, and comparable to cephalosporins for pneumococci, hemolytic and Streptococcus viridans. LVLX has strong anti-Pseudomonas aeruginosa activity, MIC50 and MIC90 were 0.5 and 64μg / ml, and amikacin and cefoperazone quite. LVLX is a broad spectrum of highly effective antimicrobials.